
Lyell Immunopharma (LYEL) Stock Forecast & Price Target
Lyell Immunopharma (LYEL) Analyst Ratings
Bulls say
Lyell Immunopharma Inc has demonstrated a strong financial position, ending the latest quarter with cash, cash equivalents, and marketable securities totaling $320 million, a $23 million increase from the previous quarter, driven primarily by a successful private placement. The company's advance in clinical data, particularly the positive outcomes associated with product candidates like LYL273 in third-line colorectal cancer (CRC), suggests a solidification of its competitive position within the CAR-T market. Enhanced expert feedback and rising probability of approval for its treatments underscore the company’s potential for success in capturing a larger market share, particularly in solid tumors beyond its current focus.
Bears say
The financial analysis of Lyell Immunopharma Inc. highlights several fundamental concerns that contribute to a negative outlook on the company's stock. A notable decrease in R&D spending from $34.9 million to $28.2 million between the second and third quarters of 2025 raises questions about the company's commitment to advancing its clinical pipeline. Additionally, critical risks remain unaddressed, including challenges in capturing market share in the CAR-T market, potential declines in treatment efficacy, emerging safety concerns, and the possibility of long-term shareholder dilution, all of which may hinder the company's prospects in a competitive market environment.
This aggregate rating is based on analysts' research of Lyell Immunopharma and is not a guaranteed prediction by Public.com or investment advice.
Lyell Immunopharma (LYEL) Analyst Forecast & Price Prediction
Start investing in Lyell Immunopharma (LYEL)
Order type
Buy in
Order amount
Est. shares
0 shares